| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30010084 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30077045 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30082748 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30081135 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30084147 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30085083 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30078680 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30024468 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30024469 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
| TVIS30024470 | HIV | ENSG00000188641.14 | protein_coding | DPYD | No | No | 1806 | Q12882 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | DPYD |
|---|---|
| DrugBank ID | DB03147 |
| Drug Name | Flavin adenine dinucleotide |
| Target ID | BE0000960 |
| UniProt ID | Q12882 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 10592235 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |
| Groups | Approved |
| Direct Classification | Flavin nucleotides |
| SMILES | CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC3=C1N=CN=C3N)C1=NC(=O)NC(=O)C1=N2 |
| Pathways | Cerivastatin Action Pathway; Ethylmalonic Encephalopathy; 3-Methylglutaconic Aciduria Type III; Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency); Caffeine Metabolism; Isovaleric Aciduria; Lysine Degradation; Riboflavin Metabolism; 5-Oxoprolinuria; Methylmalonic Aciduria Due to Cobalamin-Related Disorders; Glycerol Phosphate Shuttle; Propionic Acidemia; Hypercholesterolemia; Xanthine Dehydrogenase Deficiency (Xanthinuria); S-Adenosylhomocysteine (SAH) Hydrolase Deficiency; Tryptophan Metabolism; Glutaric Aciduria Type I; 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I; Phenylketonuria; Glycine N-Methyltransferase Deficiency; Dimethylglycine Dehydrogenase Deficiency; Lovastatin Action Pathway; 3-Methylglutaconic Aciduria Type IV; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Glutathione Metabolism; Folate Metabolism; Valine, Leucine, and Isoleucine Degradation; Maple Syrup Urine Disease; Glycerol Kinase Deficiency; Adenylosuccinate Lyase Deficiency |
| PharmGKB | |
| ChEMBL | CHEMBL1232653 |
